spirolactone

PreclinicalSmall molecule

SSecond Xiangya Hospital of Central South University

spirolactone is one of 5 small molecule programs targeting Peritoneal Dialysis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peritoneal DialysisUnknown status

Peritoneal DialysisPreclinical

Unknown status

Competition

Competitive Landscape

6 competitors in Peritoneal Dialysis

#DrugCompanyPhaseTrials

Jardiance

Boehringer Ingelheim

Phase 3

1 2

Bactroban

PPadagis LLC

Preclinical

1 3

Lotensin

VValidus Pharmaceuticals

Preclinical

1 4

Iron Isomaltoside

TThomas Jefferson University

Preclinical

1 5

spirolactone

SSecond Xiangya Hospital of Central South University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Peritoneal Dialysis1 trial

Residual Renal Function Preservation in Peritoneal Dialysis Patients

Unknown status·SSecond Xiangya Hospital of Central South University·N/A·NCT02190318·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for spirolactone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — spirolactone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for spirolactone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Xiangya Hospital of Central South University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSecond Xiangya Hospital of Central South University

spirolactone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Peritoneal Dialysis1 trial

References

Drug Info

Quick Facts

Related News